<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-473" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lichen Planopilaris</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lepe</surname>
            <given-names>Kenia</given-names>
          </name>
          <aff>Universidad de Guadalajara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nassereddin</surname>
            <given-names>Ali</given-names>
          </name>
          <aff>WakeMed Health and Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salazar</surname>
            <given-names>Francisco J.</given-names>
          </name>
          <aff>Universidad De Guadalajara</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kenia Lepe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Nassereddin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Francisco Salazar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-473.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lichen planopilaris is an inflammatory, primary cicatricial alopecia,&#x000a0;resulting in several hair loss patterns. Alopecia is considered a follicular variant of lichen planus.&#x000a0;Lichen planopilaris is the prototypical lymphocytic cicatricial alopecia, according to the North American Hair Research Society (NAHRS).&#x000a0;The condition is considered a follicular variant of lichen planus based on clinical and histopathological findings. The most widely accepted theory states that&#x000a0;lichen planopilaris is a hair-specific autoimmune disorder in which activated T-lymphocytes target follicular antigens. The incidence of any of the cicatricial alopecias is not precisely known. Lichen planopilaris has been reported as the most frequent primary scarring alopecia, accounting for 43% of cases in a series involving 72 patients. Frontal fibrosing alopecia and Graham-Little syndrome are considered variants of lichen planopilaris.</p>
        <p>This activity describes<bold>&#x000a0;</bold>the epidemiology, genetics, clinical presentation, and management of lichen planopilaris, equipping clinicians with the knowledge to improve patient care. Interprofessional collaboration between primary care clinicians and consulting dermatologists is crucial for maintaining the&#x000a0;quality of life.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Interpret&#x000a0;the epidemiology of lichen planopilaris using available evidence-based data to counsel patients.</p></list-item><list-item><p>Compare the clinical findings of lichen planopilaris to dermatological conditions with similar presentations.</p></list-item><list-item><p>Determine the treatment considerations for patients with lichen planopilaris by integrating patient history, medication compliance, and extent of alopecia.</p></list-item><list-item><p>Implement interprofessional team strategies for improving care coordination provided to patients with lichen planopilaris.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=473">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-473.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lichen planopilaris is an inflammatory, primary cicatricial alopecia that presents with different hair loss patterns. Similar to lichen planus, the etiology of lichen planopilaris is unknown but is presumably related to the cause of lichen planus.<xref ref-type="bibr" rid="article-473.r1">[1]</xref><xref ref-type="bibr" rid="article-473.r2">[2]</xref><xref ref-type="bibr" rid="article-473.r3">[3]</xref>&#x000a0;Lichen planopilaris&#x000a0;results in patchy,&#x000a0;progressive, permanent hair loss, mainly affecting the scalp while also extending to other hair-bearing regions such as the eyebrows and pubic area.<xref ref-type="bibr" rid="article-473.r4">[4]</xref>&#x000a0;Understanding&#x000a0;the&#x000a0;nature of autoimmune diseases and the role of inflammatory processes is crucial in guiding treatment decisions.</p>
        <p>The epidemiology of lichen planopilaris, a dermatological condition, is also unclear. Recent evidence-based approaches advocate for the use of corticosteroids, topical tacrolimus, antimalarial drugs, and emerging treatments such as JAK inhibitors. In addition, patient education, interdisciplinary collaboration, and long-term management strategies are critical&#x000a0;for improving functionality, considering the significant impact on lifestyle and appearance.</p>
      </sec>
      <sec id="article-473.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Lichen planopilaris is the prototypical lymphocytic cicatricial alopecia, according to the North American Hair Research Society (NAHRS).&#x000a0;This condition is considered a follicular variant of lichen planus based on clinical and histopathological findings. The most widely accepted theory states that&#x000a0;the condition is a hair-specific autoimmune disorder&#x000a0;where activated T-lymphocytes target follicular antigens.<xref ref-type="bibr" rid="article-473.r5">[5]</xref><xref ref-type="bibr" rid="article-473.r6">[6]</xref></p>
        <p>The exact etiological cause of lichen planopilaris is unknown. However,&#x000a0;signs of alopecia are believed to be a&#x000a0;cytotoxic&#x000a0;autoimmune&#x000a0;response to a yet unknown&#x000a0;antigen present&#x000a0;in hair follicles. The disease is rarely induced by genetic factors or drugs. However, there may be a correlation with monoclonal antibodies such as pembrolizumab.<xref ref-type="bibr" rid="article-473.r7">[7]</xref><xref ref-type="bibr" rid="article-473.r8">[8]</xref>&#x000a0;The use of nilotinib is also linked.<xref ref-type="bibr" rid="article-473.r9">[9]</xref></p>
      </sec>
      <sec id="article-473.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of any of the cicatricial alopecias is not precisely known. Lichen planopilaris has been reported as the most frequent primary scarring alopecia, accounting for 43% of cases in a series involving 72 patients. Frontal fibrosing alopecia and Graham-Little syndrome are considered variants of lichen planopilaris.&#x000a0;The alopecia typically affects women between ages 40&#x000a0;and 60, more often compared to men. Up to 50% of patients may develop characteristic lichen planus lesions that affect the skin, mucous membranes, or nails.<xref ref-type="bibr" rid="article-473.r10">[10]</xref><xref ref-type="bibr" rid="article-473.r11">[11]</xref></p>
      </sec>
      <sec id="article-473.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cell-mediated immunity plays a significant role in triggering the clinical expression of lichen planopilaris. This cell-mediated reaction is potentially initiated by the action of endogenous or exogenous agents, such as drugs, viruses, or contact sensitizers that bind to keratinocytes as well as follicular epithelium. Contact sensitizers, such as gold, mercury, and cobalt metals, could act as haptens and evoke an inflammatory reaction. Microorganisms that may play a role include the hepatitis C virus, HIV, herpes simplex virus type 2, human papillomavirus, and syphilis. Antimalarial agents, gold, beta-blockers, thiazide diuretics, and angiotensin-converting enzyme inhibitors are involved.</p>
        <p>Following&#x000a0;this initial trigger, keratinocytes and hair follicles may act as signal transducers, capable of converting these stimuli into cytokines and chemotactic factors to initiate and perpetuate inflammation. Most infiltrated T-lymphocytes are concentrated around the bulge area. Lineage studies have demonstrated that cells within the bulge area are multipotent, and their progeny generates new lower anagen hair follicles. The failure of affected follicles to regenerate is believed to be due to the destruction of follicular stem cells in the bulge area.<xref ref-type="bibr" rid="article-473.r12">[12]</xref><xref ref-type="bibr" rid="article-473.r13">[13]</xref><xref ref-type="bibr" rid="article-473.r14">[14]</xref></p>
      </sec>
      <sec id="article-473.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A band-like mononuclear infiltrate obscuring the interface between the follicular epithelium and the dermis is observed in lichen planopilaris. The epithelial-stromal junction may have prominent vacuoles and dyskeratosis with individually necrotic, polygonal basal keratinocytes. Inflammation affects the upper portion of the follicle most severely, but&#x000a0;this may extend down the length of the follicle. Perifollicular fibrosis and chronic inflammation&#x000a0;are observed in later stages. Ultimately, follicles are replaced by columns of sclerotic collagen called follicular scars. Elastic tissue stains can be used to highlight these scars. Grouped globular immunofluorescence,&#x000a0;typically IgM, especially when found adjacent to the follicular epithelium, is the characteristic pattern observed in lichen planopilaris. This pattern is in contrast to chronic cutaneous lupus erythematosus, where linear deposits of immunoreactants are typical.<xref ref-type="bibr" rid="article-473.r15">[15]</xref></p>
      </sec>
      <sec id="article-473.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical course of hair loss in lichen planopilaris may be insidious or fulminant, and the pattern is highly variable. Several scattered foci of partial hair loss are commonly associated with perifollicular erythema and scaling. A pattern of hair loss suggestive of central centrifugal alopecia or Brocq alopecia can also occur. The scalp lesions may be single or multiple, focal or diffuse, and occur anywhere on the scalp (see <bold>Image.&#x000a0;</bold>Patient with Lesions of Lichen Planopilaris). Hair follicles around the margins of the bare areas show perifollicular erythema and perifollicular scale, unlike discoid lupus erythematosus, where follicular plugging is in the center of the active bare patch (see <bold>Image.</bold>&#x000a0;Dermoscopic and Clinical Findings in Lichen Planopilaris).</p>
        <p>A pull test may yield anagen hairs in cicatricial alopecia, indicating active disease requiring treatment. Symptoms&#x000a0;such as itching, burning, pain, and tenderness are often severe. Cutaneous, nail, and mucous membrane lichen planus may occur before, during, or after the onset of scalp involvement. Perifollicular scaling is the most characteristic trichoscopic feature of active lichen planopilaris. Trichoscopy of inactive end-stage lichen planopilaris reveals small, irregularly shaped, whitish areas lacking follicular openings, called fibrotic white dots, and white areas of conducted fibrosis.<xref ref-type="bibr" rid="article-473.r16">[16]</xref></p>
      </sec>
      <sec id="article-473.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis is based on the clinicopathologic correlation rather than solely on clinical signs and symptoms. A 4-mm-deep punch biopsy specimen should be submitted for horizontal sectioning and hematoxylin-eosin staining.&#x000a0;The best biopsy site is an active, symptomatic hair-bearing area with perifollicular erythema and perifollicular scale located at the margin of a bare patch with a positive anagen pull test.<xref ref-type="bibr" rid="article-473.r17">[17]</xref></p>
      </sec>
      <sec id="article-473.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The main objectives of treatment are to reduce hair loss, control the symptoms, and stop the scarring process.&#x000a0;Regrowth should not be expected as the complete elimination of inflammation is unlikely. As no consistent markers measure the disorder's progress, therapy is based on perceived severity and patient tolerance to treatment. The duration of treatment should be guided by clinical response and relapse rates. General measures include avoiding chemical or physical insults to the hair, such as coloring or perming. Contrary to many patients' beliefs, the frequency of shampooing does not impact overall hair loss. Potent corticosteroids and topical tacrolimus are commonly used in all forms of primary cicatricial alopecia and are frequently considered first-line treatments. <xref ref-type="bibr" rid="article-473.r10">[10]</xref>&#x000a0;Antimalarial drugs are commonly used to treat lichen planopilaris. Hydroxychloroquine at a dose of 200 mg twice daily is generally used and is often considered first-line systemic therapy. Improvement is often observed within 6 months. Minoxidil helps maximize the hair growth of the remaining follicles. Recently, JAK inhibitors&#x000a0;such as baricitinib and tofacitinib have been used to treat lichen planopilaris.<xref ref-type="bibr" rid="article-473.r18">[18]</xref><xref ref-type="bibr" rid="article-473.r19">[19]</xref></p>
        <p>A new scoring system, the lichen planopilaris activity index, has been introduced to monitor treatment response and document disease progression.&#x000a0;This system assigns numerical values to subjective and objective markers of the disease: symptoms (pruritus, pain, burning) and signs (erythema, perifollicular erythema, perifollicular scale), a measure of the activity (anagen pull test), and spreading of the condition&#x02014;statistical&#x000a0;comparison of pretreatment and posttreatment responses.</p>
      </sec>
      <sec id="article-473.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The most important differential diagnosis may be seborrheic dermatitis, as many patients have a long history of scalp scaling, often diagnosed initially as seborrheic dermatitis. A sudden onset of patchy hair loss on the scalp may be diagnosed as alopecia areata. However, if there's only partial hair loss, perifollicular erythema, and scaling within the patch, lichen planopilaris is considered a diagnosis of high suspicion.</p>
      </sec>
      <sec id="article-473.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of&#x000a0;lichen planopilaris can vary widely among affected individuals, influenced by several factors such as the extent and severity of scalp involvement, the presence of associated signs and symptoms, the effectiveness of the treatment regimen, and individual patient characteristics. Overall, alopecia is considered a chronic and progressive condition that can lead to significant morbidity, particularly in cases of extensive and severe disease.</p>
      </sec>
      <sec id="article-473.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Some potential complications of&#x000a0;lichen planopilaris include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Permanent hair loss (cicatricial alopecia):&#x000a0;Lichen planopilaris can result in irreversible destruction of hair follicles, leading to scarring and permanent hair loss in affected areas of the scalp.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Scarring and fibrosis: The chronic inflammation characteristic of&#x000a0;lichen planopilaris can lead to significant scarring and fibrosis within the affected scalp tissue. This scarring may cause scalp tightness, pain, and discomfort and can also affect the ability of remaining hair follicles, decreasing their functionality.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Follicular hyperkeratosis:&#x000a0;Lichen planopilaris&#x000a0;can accumulate keratin around the hair follicles, leading to hyperkeratosis. This condition may manifest as rough, scaly patches on the scalp, contributing to itching, irritation, and further inflammation.</p>
          </list-item>
          <list-item>
            <p>Secondary infections: Persistent inflammation and compromised skin barrier function may&#x000a0;subject affected individuals to secondary bacterial or fungal infections of the scalp area. These infections can exacerbate existing symptoms such as itching, pain, and inflammation and may require additional treatment with antibiotics or antifungal medications.</p>
          </list-item>
          <list-item>
            <p>Psychological impact: The visible changes associated with lichen planopilaris, including hair loss, scarring, and scalp abnormalities, can have a noteworthy psychological impact on affected individuals, leading to decreased self-esteem, anxiety, and depression. Therefore, managing the psychosocial aspects of&#x000a0;lichen planopilaris is an essential component of comprehensive care for these patients.</p>
          </list-item>
          <list-item>
            <p>Ocular involvement: In rare cases,&#x000a0;lichen planopilaris can extend beyond the scalp and involve the eyebrows and eyelashes. Eyebrow and eyelash loss can occur, leading to cosmetic concerns and potential eye irritation or discomfort.<xref ref-type="bibr" rid="article-473.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Early diagnosis, treatment compliance, and close monitoring by dermatologists and multidisciplinary care are necessary to optimize outcomes for individuals with lichen planopilaris.</p>
      </sec>
      <sec id="article-473.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education are important components for effectively managing cases of lichen planopilaris.&#x000a0;Providing patients with knowledge about their clinical condition promotes treatment adherence and mitigates potential complications. Patients should be informed about the signs and symptoms of lichen planopilaris, such as scalp itching, burning, and hair loss, to facilitate early recognition and prompt medical evaluation. Encouraging patients to seek medical attention if they notice any concerning changes in their scalp or hair is crucial. Once treatment begins, patients should be counseled to follow treatment with compliance. Addressing the psychosocial impact of the disease through supportive guidance and counseling is also essential.</p>
      </sec>
      <sec id="article-473.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lichen planopilaris&#x000a0;is best managed by a dermatologist. However, the patient may initially be seen by a&#x000a0;primary care&#x000a0;clinician. These clinicians must refer patients with complex skin disorders to the respective specialist for treatment. Coordination between this interprofessional team improves outcomes. The primary goals of treatment are to reduce hair loss, control the symptoms, and stop the scarring process. Regrowth should not be expected as the complete elimination of inflammation is unlikely. No consistent markers measure the progress of the disorder. Therapy is based on perceived severity and patient tolerance to treatment. The duration of treatment should be guided by clinical response and relapse rates.&#x000a0;General measures include avoiding chemical or physical insults to the hair, such as coloring or perming. Some patients may benefit from hydroxychloroquine and minoxidil, but a complete response is rare. Improvement may take 6 to 9 months or longer.</p>
      </sec>
      <sec id="article-473.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=473">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/lichen-planopilaris/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=473">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/473/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=473">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-473.s16">
        <fig id="article-473.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Dermoscopic and Clinical Findings in Lichen Planopilaris. The bare areas exhibit perifollicular erythema and scaling, characteristic of lichen planopilaris. Contributed by N Sathe, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LPP" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-473.s17">
        <fig id="article-473.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Patient With Lesions of Lichen Planopilaris. Diffuse, multiple scalp lesions in a patient with lichen planopilaris. Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lichen__planopilaris__SV" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-473.s18">
        <title>References</title>
        <ref id="article-473.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ocampo-Garza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trichoscopy of Dark Scalp.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">30643773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Mesinkovska</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and use of finasteride in women: a systematic review.</article-title>
            <source>Int J Dermatol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>7</issue>
            <fpage>759</fpage>
            <page-range>759-776</page-range>
            <pub-id pub-id-type="pmid">30604525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The uses of naltrexone in dermatologic conditions.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>1746</fpage>
            <page-range>1746-1752</page-range>
            <pub-id pub-id-type="pmid">30582992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fechine</surname>
                <given-names>COC</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>NYS</given-names>
              </name>
              <name>
                <surname>Romiti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.</article-title>
            <source>An Bras Dermatol</source>
            <year>2022</year>
            <season>May-Jun</season>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-357</page-range>
            <pub-id pub-id-type="pmid">35379508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babahosseini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tavakolpour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahmoudi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Balighi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teimourpour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghodsi</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Abedini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghandi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lajevardi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kamyab</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daneshpazhooh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>598</fpage>
            <page-range>598-604</page-range>
            <pub-id pub-id-type="pmid">30411987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mernissi</surname>
                <given-names>FZ</given-names>
              </name>
            </person-group>
            <article-title>Central Frontoparietal Band-Like Alopecia in a 40-Year-Old Woman.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>351</fpage>
            <page-range>351-353</page-range>
            <pub-id pub-id-type="pmid">30410916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uthayakumar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rudd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fearfield</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma.</article-title>
            <source>Australas J Dermatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-406</page-range>
            <pub-id pub-id-type="pmid">34216144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Melendo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morales-Munera</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cubir&#x000f3;</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-S&#x000e1;nchez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mozos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x000e9;lamos</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>e15388</fpage>
            <pub-id pub-id-type="pmid">35174945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahouel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ben Salah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rouatbi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boukhriss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abdejlil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Youssef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belhadjali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laatiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zili</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nilotinib-induced lichen planopilaris.</article-title>
            <source>Int J Dermatol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>e37</fpage>
            <page-range>e37-e38</page-range>
            <pub-id pub-id-type="pmid">33937983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Lichen Planopilaris.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-209</page-range>
            <pub-id pub-id-type="pmid">35120689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naeini</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Saber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faghihi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lichen planopilaris: A review of evaluation methods.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>442</fpage>
            <page-range>442-445</page-range>
            <pub-id pub-id-type="pmid">33871194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taguti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;eb</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Lichen Planopilaris Caused by Wig Attachment: A Case of Koebner Phenomenon in Frontal Fibrosing Alopecia.</article-title>
            <source>Int J Trichology</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>172</fpage>
            <page-range>172-174</page-range>
            <pub-id pub-id-type="pmid">30386077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doche</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Ericson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Romiti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McAdams</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Hordinsky</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Evidence for neurogenic inflammation in lichen planopilaris and frontal fibrosing alopecia pathogenic mechanism.</article-title>
            <source>Exp Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-285</page-range>
            <pub-id pub-id-type="pmid">30408256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imhof</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Torgerson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Tolkachjov</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Frontal Fibrosing Alopecia in Women: The Mayo Clinic Experience With 148 Patients, 1992-2016.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>1581</fpage>
            <page-range>1581-1588</page-range>
            <pub-id pub-id-type="pmid">30392542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasiri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bidari Zerehpoosh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abdollahimajd</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Younespour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esmaili Azad</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A comparative immunohistochemical study of epidermal and dermal/perifollicular Langerhans cell concentration in discoid lupus erythematosus and lichen planopilaris: a cross-sectional study.</article-title>
            <source>Lupus</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>14</issue>
            <fpage>2200</fpage>
            <page-range>2200-2205</page-range>
            <pub-id pub-id-type="pmid">30376791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alessandrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Starace</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Common causes of hair loss - clinical manifestations, trichoscopy and therapy.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-640</page-range>
            <pub-id pub-id-type="pmid">33290611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svigos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lo Sicco</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>681</fpage>
            <page-range>681-692</page-range>
            <pub-id pub-id-type="pmid">34347282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motamed-Sanaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khazaee</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Shokrgozar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alishahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahramiyanpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Amani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>JAK inhibitors in lichen planus: a review of pathogenesis and treatments.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>3098</fpage>
            <page-range>3098-3103</page-range>
            <pub-id pub-id-type="pmid">35997540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>JAK Inhibitors in the Treatment of Lichen Planopilaris.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-17</page-range>
            <pub-id pub-id-type="pmid">38313572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-473.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz-Lozano</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Camarena</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Valdez-Garcia</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Roman-Zamudio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herrera-Rodriguez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Andrade-Carrillo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garza-Garza</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cardenas-de la Garza</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Ocular involvement and complications of lichen planus, lichen planus pigmentosus, and lichen planopilaris: A comprehensive review.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>e15137</fpage>
            <pub-id pub-id-type="pmid">34541780</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
